SEP 11, 2015 10:08 PM PDT

AML Answer

A protein domain may be critical to helping patients fighting acute myeloid leukemia (AML) avoid a relapse. Researchers at Rice University, working with colleagues at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center, have developed a small molecule that could deliver a “one-two punch” to proteins that resist chemotherapy in patients with AML.

Small molecule helps patients fight acute myeloid leukemia.

Called STAT3, the protein interferes with chemotherapy by halting the death of cancerous cells and enabling them to grow. The molecule discovered at Rice finds and then attacks a previously unknown binding site on STAT3, disrupting its disease-promoting properties. The work led by Rice chemist Zachary Ball, Baylor pediatrician Michele Redell and MD Anderson oncologist David Tweardy appears in the journal Angewandte Chemie and is reported in Bioscience Technology

An earlier discovery by Ball’s lab led to the discovery and exploitation of this new drug target. That discovery enabled researchers to identify, on a molecular level, the target of action for drug molecules by using rhodium-based inorganic complexes. The complexes recognize specific folds in a protein chain and catalyze minute changes in those sequences, thus forming a “tag” for later analysis.

The STAT3 protein (“signal transducer and activator of transcription 3″) is a suspected culprit in the relapse of nearly 40 percent of children who have AML. The new proximity-driven rhodium(II) catalyst known as MM-206 seeks and modifies an inhibitor-binding site on the protein and delivers the inhibitor, naphthalene sulfonamide, to the modified site.

According to Ball, “This is the confluence of two ideas we’ve been working on around what you can do with conjugates linked to rhodium.”

Redell, who is also part of the leukemia and lymphoma teams at Texas Children’s Hospital, added, “We know that increased activity of STAT3 in AML and other cancers helps the cancer cells survive chemotherapy, so any new strategy we can develop to stop that process could mean real benefit for our patients.”

Ball explained that STAT3 has been a target for scientists trying to shut down cancer cells, saying, ”STAT fits in the broad category of what are called ‘undruggable protein-protein interactions.’ There’s a large surface area with weak interactions for which we have typically failed to find good drugs.”

Prior research revolved around only one region of STAT3, its SH2 domain, with limited success. Ball added, “There’s no evidence people have tried to go after the coiled coil as a drug target. Our main advance, from a medicinal perspective, is that this compound also works in a mouse model. All the other compounds worked in cells, but in mice, they weren’t potent enough or stable enough. The discovery raises new questions about STAT3 biology and points the way to future anti-cancer approaches, including combination therapies of coiled-coil STAT3 inhibitors in tandem with other agents.”
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 04, 2018
Cancer
SEP 04, 2018
Metal beads that could help reduce chemotherapy side effects in brain tumor
Brain tumors are one of the most challenging types of cancers to treat. Only 1 in 7 patients will survive the disease, and those survivors will usually suffer from lots of side effects becaus...
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
NOV 05, 2018
Cell & Molecular Biology
NOV 05, 2018
Using Imaging to Understand Cancer Growth
Most types of cells in our body go through a critical renewal process in which cells divide into two new ones. But it can get out of control as well....
DEC 04, 2018
Drug Discovery
DEC 04, 2018
Drug Combination May Be Effective for Melanoma
Protein kinase inhibitors have been noted to be the most effective class of drugs in the treatment of melanoma—a deadly skin cancer of the melanocyte...
DEC 06, 2018
Drug Discovery
DEC 06, 2018
Repurposing Cancer Drugs For HPV Treatment
Drug repurposing is transforming the health care world. The idea that old, previously-- FDA approved drugs could be altered and to be used again for the tr...
DEC 09, 2018
Health & Medicine
DEC 09, 2018
Health Beliefs That Influence Skin Cancer
  In the U.S., there are over 3.5 million cases of skin cancer reported every year. Basal cell carcinoma and squamous cell carcinoma are the most comm...
Loading Comments...